SPARE-AD also correlated with the CSF T-tau/Aβ42 ratio, which discriminates between AD patients and CN individuals [29], distinguishes patients with AD from those with FTLD [96], and predicts future cognitive impairment [97], [98]. This evidence concerns the gene MAPT and Alzheimer disease.